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Abstract
BACKGROUND—Currently, no single U.S. surveillance system can provide estimates of the 
burden of all types of health care–associated infections across acute care patient populations. We 
conducted a prevalence survey in 10 geographically diverse states to determine the prevalence of 
health care–associated infections in acute care hospitals and generate updated estimates of the 
national burden of such infections.
METHODS—We defined health care–associated infections with the use of National Healthcare 
Safety Network criteria. One-day surveys of randomly selected inpatients were performed in 
participating hospitals. Hospital personnel collected demographic and limited clinical data. 
Trained data collectors reviewed medical records retrospectively to identify health care–associated 
infections active at the time of the survey. Survey data and 2010 Nationwide Inpatient Sample 
data, stratified according to patient age and length of hospital stay, were used to estimate the total 
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numbers of health care–associated infections and of inpatients with such infections in U.S. acute 
care hospitals in 2011.
RESULTS—Surveys were conducted in 183 hospitals. Of 11,282 patients, 452 had 1 or more 
health care–associated infections (4.0%; 95% confidence interval, 3.7 to 4.4). Of 504 such 
infections, the most common types were pneumonia (21.8%), surgical-site infections (21.8%), and 
gastrointestinal infections (17.1%). Clostridium difficile was the most commonly reported 
pathogen (causing 12.1% of health care–associated infections). Device-associated infections (i.e., 
central-catheter–associated bloodstream infection, catheter-associated urinary tract infection, and 
ventilator-associated pneumonia), which have traditionally been the focus of programs to prevent 
health care–associated infections, accounted for 25.6% of such infections. We estimated that there 
were 648,000 patients with 721,800 health care–associated infections in U.S. acute care hospitals 
in 2011.
CONCLUSIONS—Results of this multistate prevalence survey of health care–associated 
infections indicate that public health surveillance and prevention activities should continue to 
address C. difficile infections. As device- and procedure-associated infections decrease, 
consideration should be given to expanding surveillance and prevention activities to include other 
health care–associated infections.
Elimination of health care–associated infections is a priority of the Department of Health 
and Human Services.1 Considerable success in prevention has been reported for some 
infections, particularly central-catheter–associated bloodstream infections.2–5 Continued 
improvements in patient safety depend on maintaining a comprehensive understanding of 
the epidemiology of health care–associated infections. Currently, no single U.S. surveillance 
system can provide estimates of the burden of all types of such infections across acute care 
patient populations. The most recent estimate produced by the Centers for Disease Control 
and Prevention (CDC) and published in 2007 — 1.7 million health care–associated 
infections per year — relied on historical data combined with contemporary hospitalization 
data.6 The CDC surveillance system for health care–associated infections, the National 
Healthcare Safety Network (NHSN), provides information on incidence rates of common 
infections. Most hospitals limit reporting to device-associated infections, selected surgical-
site infections, and infections due to Clostridium difficile and methicillin-resistant 
Staphylococcus aureus (MRSA). Therefore, the NHSN cannot provide national-scale data 
on the overall burden and distribution of health care–associated infections across acute care 
patient populations.
To address this knowledge gap, the CDC began a three-phase effort in 2009 to develop and 
conduct a multistate prevalence survey of health care–associated infections and use of 
antimicrobial agents. Prevalence surveys have been used in other countries to describe the 
scope and magnitude of the problem of such infections.7–30 The CDC effort culminated in 
2011 in a large-scale survey that estimated the prevalence of health care–associated 
infections in acute care hospitals, determined the distribution of these infections according to 
infection site and pathogen, and generated updated estimates of the national burden of these 
infections.
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SURVEY DESIGN AND HOSPITAL SELECTION
Survey methods were developed in two phases: a single-city pilot in 200931 and a limited-
rollout survey in 2010 that was performed in collaboration with the Emerging Infections 
Programs (EIP), a network of 10 state health departments (in California, Colorado, 
Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and 
Tennessee) and academic partners. The current survey was also conducted with the EIP.
Each EIP site was asked to recruit a total of up to 25 general and children’s acute care 
hospitals, with the following distribution according to size, if possible: 13 small hospitals 
(<150 beds), 9 medium-sized hospitals (150 to 399 beds), and 3 large hospitals (≥400 beds). 
Eligible hospitals were randomly selected within each size stratum to participate in a 1-day 
survey. When a selected hospital declined to participate, an alternative hospital was used.
The CDC determined the survey to be a public health surveillance activity. Institutional 
review boards at the state health departments, academic partners, and participating hospitals 
(where applicable) reviewed the protocol and either determined that the survey did not 
constitute human-subjects research or approved the survey with a waiver of the requirement 
for informed consent.
PATIENT SELECTION
Inpatients of any age in acute care hospitals were eligible for inclusion. Patients in outpatient 
areas, emergency departments, and psychiatry, skilled nursing, and rehabilitation units were 
excluded. Each hospital surveyed a random sample of eligible patients obtained from the 
morning census on the survey date: 100 patients in each large hospital and 75 patients (or all 
eligible patients if <75) in each small or medium-sized hospital (for details, see the 
Supplementary Appendix, available with the full text of this article at NEJM.org).
TRAINING AND DATA COLLECTION
Two teams collected data in each hospital: a primary team of infection preventionists and 
other personnel at the participating hospital and an EIP team of staff members from state 
health departments, academic partner institutions, or both. Both teams received training in 
survey operations and data-collection procedures; the EIP team also received training in 
NHSN terms and definitions for health care–associated infections.
Primary teams reviewed medical records on the survey date to collect demographic and 
limited clinical information, including whether patients were receiving or were scheduled to 
receive antimicrobial drugs at the time of the survey. Primary teams did not collect detailed 
antimicrobial data or identify health care–associated infections. In some cases, EIP teams 
assisted with or performed the primary-team data collection.
EIP teams reviewed medical records retrospectively to collect data on antimicrobial therapy 
and identify active health care–associated infections with the use of NHSN surveillance 
definitions in place at that time.32 EIP teams were instructed to use only information present 
in the medical record on or before the survey date, including results of cultures collected or 
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other testing performed on or before the survey date. EIP teams used the NHSN definitions 
of gastrointestinal infections for reporting C. difficile infection when possible; in 
circumstances in which a patient with a positive test result for C. difficile infection did not 
meet the NHSN gastrointestinal definitions, EIP teams used a prevalence survey–specific 
definition of C. difficile infection (described in the Supplementary Appendix).
On the basis of pilot data31 and unpublished data showing that antimicrobial therapy is a 
sensitive proxy indicator for health care–associated infections (sensitivity, 95 to 100%), EIP 
teams reviewed records for active health care–associated infections only for those patients 
who were receiving antimicrobial agents for the treatment of active infections or for no 
documented reason. Additional information on the use of data on antimicrobial therapy to 
identify patients with active infections is presented in the Supplementary Appendix 
(Methods section and Fig. S1).
Active health care–associated infections were defined as infections not present or incubating 
on admission to the survey hospital (with certain exceptions, noted below) that met NHSN 
surveillance definition criteria, with signs or symptoms of infection present on the survey 
date or with antimicrobial therapy still being given on the survey date. Infections present on 
admission to the survey hospital were considered health care–associated infections if they 
were surgical-site infections related to surgery performed at the survey hospital within the 
preceding 30 days (or within 1 year if an implant was in place), C. difficile infections related 
to a previous stay in the survey hospital within 28 days before specimen collection, or 
infections related to a prior hospitalization in the survey hospital within the preceding 48 
hours.
STATISTICAL ANALYSIS
Data were analyzed with the use of SAS software, version 9.3 (SAS Institute), and OpenEpi 
software, versions 2.3.1 and 3.01 (www.openepi.com). The mid-P exact method was used to 
generate confidence intervals for infection prevalence. Comparisons of patients with and 
those without health care–associated infections were performed with the use of chi-square 
tests for categorical variables and Wilcoxon rank-sum tests for continuous variables.
To generate estimates of the national burden of health care–associated infections, we 
converted infection prevalence to incidence using the formula of Rhame and Sudderth33: 
I=P×[LA÷(LN-INT)], where I denotes incidence, P prevalence, LA the mean length of 
hospitalization for all patients, LN the mean length of hospitalization for patients who 
acquired one or more health care–associated infections, and INT the mean interval between 
admission and the onset of the first such infection. Numbers of patients with health care–
associated infections were obtained by multiplying infection incidence by numbers of U.S. 
hospital discharges, obtained from the 2010 Nationwide Inpatient Sample (NIS).34 This 
database of hospitalizations from a sample of U.S. community hospitals was developed as 
part of the Healthcare Cost and Utilization Project of the Agency for Healthcare Research 
and Quality; discharge weighting allows national estimates to be generated from the sample.
We sought to improve the precision of the burden-estimation process by performing log-
binomial regression modeling to identify factors significantly associated with the prevalence 
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of health care–associated infections. Through a process described in the Supplementary 
Appendix, the results of regression modeling were used to create multiple strata based on 
patient age and a proxy measure of the length of the hospital stay. Within each stratum, the 
predicted prevalence of health care–associated infections was converted to incidence with 
the use of the median length of the hospital stay for surveyed patients for whom such 
information was available (LA in the formula of Rhame and Sudderth), the median length of 
hospital stay for patients with health care–associated infections (LN), and the median 
interval from admission to the onset of the first health care–associated infection (INT). 
Median rather than mean values were used owing to a skewed distribution. The incidence in 
each stratum of age and length of stay was multiplied by the total number of U.S. discharges 
in that stratum (with the use of weighted discharge data from the NIS), under the assumption 
that each discharge represented a unique patient, to get stratum-specific numbers of patients 
with health care–associated infections. These stratum-specific numbers were summed to 
obtain an estimate of the total number of inpatients with health care–associated infections in 
U.S. acute care hospitals in 2011. Because our estimates of the median length of the hospital 
stay for all patients were based on data from patients receiving antimicrobial therapy, who 
may have had a longer median length of stay than patients not receiving such therapy, we 
also performed the burden-estimation process using data from the NIS for the median length 
of the hospital stay for all patients in the formula of Rhame and Sudderth.
Burden estimates for major types of health care–associated infection were generated by 
multiplying the proportion of surveyed patients with each infection type by the estimated 
total number of patients with health care–associated infections. The numbers of each major 
type of infection were summed to obtain an estimate of the total number of inpatient health 
care–associated infections in U.S. acute care hospitals in 2011.
RESULTS
HOSPITALS AND PATIENTS
A total of 183 hospitals (79% of the goal of 232 hospitals) participated (Table S1 in the 
Supplementary Appendix). Of the 183 hospitals, 93 (51%) were small, 68 (37%) were 
medium-sized, and 22 (12%) were large — proportions that were similar to those for all 406 
hospitals in the 10 EIP sites (55% small, 35% medium-sized, and 10% large).
Overall, 11,290 patients were included in surveys performed between May and September 
2011; data collection was completed for 11,282 patients (99.9%). The median patient age 
was 58 years (interquartile range, 32 to 74). Most patients (71.2%) were in non-nursery 
wards; 15.1% were in critical care units. Approximately 51.9% of patients were receiving or 
were scheduled to receive antimicrobial agents at the time of the survey (Table 1, and Fig. 
S1 in the Supplementary Appendix).
PREVALENCE AND DISTRIBUTION OF HEALTH CARE–ASSOCIATED INFECTIONS
The medical records of 4504 patients (39.9%) — those receiving antimicrobial agents for 
treatment of active infections or for no documented reason — were reviewed for health 
care–associated infections (Fig. S1 in the Supplementary Appendix). A total of 504 such 
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infections were detected in 452 of 11,282 patients; therefore, 4.0% of patients had at least 1 
health care–associated infection (95% confidence interval [CI], 3.7 to 4.4). Pneumonia and 
surgical-site infection were most common, followed by gastrointestinal infection, urinary 
tract infection, and primary bloodstream infection (Table 2). In addition to 50 primary 
bloodstream infections, there were 37 secondary bloodstream infections. Device-associated 
infections (i.e., ventilator-associated pneumonia, catheter-associated urinary tract infection, 
and central-catheter–associated bloodstream infection) accounted for 25.6% of all health 
care–associated infections; together, device-associated infections and surgical-site infections 
(21.8%) accounted for 47.4% of all health care–associated infections (239 of 504 
infections). The remaining 52.6% of infections were not associated with devices or operative 
procedures.
Overall, 169 of 394 non–surgical-site infections (42.9%) developed during or within 48 
hours after a stay in a critical care unit; 167 (42.4%) developed during or within 48 hours 
after a stay in a non-nursery ward. The NHSN operative-procedure types associated with the 
most surgical-site infections were colon surgeries (accounting for 16 of 110 surgical-site 
infections [14.5%]), hip arthroplasties (11 [10.0%]), and small-bowel surgeries (7 [6.4%]). 
Ten surgical-site infections (9.1%) were attributed to other, unspecified procedures.
The median interval from hospital admission to the onset of symptoms of a health care–
associated infection was 6 days (interquartile range, 2 to 13) among 494 patients for whom 
symptom-onset dates were reported. Overall, 98 health care–associated infections (19.4%) 
were present on admission and were therefore related to a previous admission to the same 
hospital. Most infections present on admission were surgical-site infections (66 [67.3%]) 
and gastrointestinal infections (9 [9.2%]). The outcome was known for 436 of the 452 
patients with health care–associated infections (96.5%). Fifty of these 436 patients (11.5%) 
died during their survey hospitalization.
PATHOGENS CAUSING HEALTH CARE–ASSOCIATED INFECTIONS
A total of 481 pathogens were reported for 372 of 504 health care–associated infections 
(73.8%). C.difficile was the most common pathogen, causing 61 health care–associated 
infections (12.1%) (Table 3). S. aureus was the second most common pathogen (54 
infections [10.7%]), followed by Klebsiella pneumoniae and K. oxytoca (50 infections 
[9.9%]) and Escherichia coli (47 infections [9.3%]) (Table 3).
RISK FACTORS FOR HEALTH CARE–ASSOCIATED INFECTIONS AND OVERALL U.S. 
BURDEN
Multivariable regression analysis showed that patients who were older, had been in the 
hospital longer at the time of the survey, were in a large hospital, had a central catheter in 
place, were receiving mechanical ventilatory support, or were in a critical care unit had an 
increased risk of health care–associated infection (Table S2 in the Supplementary 
Appendix). The total estimated number of patients with at least 1 health care–associated 
infection in 2011 was 648,000 (95% CI, 246,400 to 987,300). The use of data on the median 
length of the hospital stay from the NIS in the burden-estimation process, in place of data on 
the length of stay from surveyed patients receiving antimicrobial therapy, did not 
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substantially change the overall burden estimate (582,000 infections; 95% CI, 216,600 to 
875,400). Estimated numbers of selected major types of health care–associated infection are 
shown in Table 4; summing the estimates for each of the 13 major types shown in Table 2 
yielded an overall total estimate of 721,800 infections (95% CI, 214,700 to 1,411,000).
DISCUSSION
In this survey, 4.0% of inpatients in U.S. acute care hospitals had at least 1 health care–
associated infection, yielding an estimate of 648,000 inpatients with a total of approximately 
721,800 such infections in 2011. These estimates of the national burden of health care–
associated infections in acute care hospitals were generated through the use of a modeling 
process that accounted for selected predictors of infection prevalence, including age and 
length of stay, and application of the results of this modeling to the NIS, a nationally 
representative sample of U.S. community-hospital stays. The current estimates of the overall 
burden are lower than older estimates, such as those from the Study on the Efficacy of 
Nosocomial Infection Control in the 1970s (2.1 million infections)36 and those from 
analyses of National Nosocomial Infections Surveillance system data collected from 1990 
through 2002 (1.7 million infections),6 although it is difficult to draw conclusions from 
these comparisons because of the differences in patient populations, surveillance definitions 
of health care–associated infections, and data-collection and analytical methods among these 
CDC efforts.31
Device-associated infections, which have been a major focus of infection prevention in 
recent decades, accounted for only 25.6% of all health care–associated infections detected in 
the current survey. Infections not associated with devices or operative procedures — 
including C. difficile infections and other gastrointestinal infections and non–ventilator-
associated pneumonia — accounted for approximately half of all health care–associated 
infections in the survey. This finding should expand the public health focus to include these 
other types of infections, identifying patients at risk and developing effective prevention 
measures. An example is the recent focus of the CDC on surveillance and prevention of C. 
difficile infections.37
Gastrointestinal infections, 70.9% of which were C. difficile infections, were the third most 
common type of health care–associated infection in this survey, in contrast to the results of 
previous analyses.6,36 Although there is ample evidence to support our finding that C. 
difficile infections are a major contributor to the overall U.S. burden of health care–
associated infections in acute care hospitals,38–41 the high prevalence of C. difficile 
infections in this survey may be partially explained by the use of a sensitive definition. This 
definition, as opposed to the more restrictive NHSN surveillance definitions of 
gastrointestinal infections, was used for reporting 31 of the 61 cases of C. difficile infection 
(51%) detected in the survey. It is also likely that nucleic acid amplification testing for 
diagnosis of C.difficile infection was used in some participating facilities, resulting in 
increased case detection.42
This survey has important limitations that must be considered. First, although we are 
confident that the survey hospitals are representative of hospitals within the EIP catchment 
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areas, they may not be representative of all U.S. acute care hospitals. Only 183 hospitals and 
11,282 patients were included, of a total of approximately 5000 U.S. community hospitals 
and 34 million annual admissions (2012 data) in the United States.43 Second, because our 
survey was limited to acute care hospitals, we cannot estimate the numbers of health care–
associated infections occurring in other settings, such as skilled nursing facilities. Third, we 
were not able to validate data across the 10 EIP sites. Data evaluations were performed in 
the previous two phases of survey development; the results showed that the primary data-
collection team and the evaluation team identified similar proportions of patients with health 
care–associated infections overall, although there were many discrepancies in patient-level 
determinations of such an infection.31 Additional limitations are discussed in the 
Supplementary Appendix.
Despite these limitations, the national estimates that we generated for selected types of 
health care–associated infection are remarkably similar to estimates from other data sources. 
For example, we estimated that 15,600 central-catheter–associated bloodstream infections 
occurred in 2011 (not including such infections in neonatal intensive care units), and NHSN 
data yielded an estimate of 12,400.35 Our estimate of 9700 hospital-onset cases of MRSA 
bacteremia is similar to that obtained from EIP population-based surveillance, in which 
71.3% of the estimated 14,156 invasive, hospital-onset MRSA infections, or 10,093 
infections, involved bacteremia.44 Finally, we estimated that there were 66,100 Surgical 
Care Improvement Project procedure-associated surgical-site infections, as compared with 
the NHSN estimate of 52,567.35 The similarity of these estimates from different data 
sources bolsters our confidence in the overall estimates of health care–associated infections 
that we have generated, as well as our estimates of infections for which other data sources 
do not currently exist.
In summary, our survey results indicate that on any given day approximately 1 of every 25 
in-patients in U.S. acute care hospitals has at least one health care–associated infection. 
Pneumonia and surgical-site infection were the most common infection types, and C. 
difficile was the most common pathogen. Infections other than those associated with central 
catheters, urinary catheters, and ventilators account for the majority of the U.S. burden of 
health care–associated infections and may warrant increased attention. A better 
understanding of trends in the epidemiology of health care–associated infections and 
prevention success may be achieved through repeated prevalence surveys in which similar 
methods are used each time.
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Table 1
Demographic and Clinical Characteristics of Surveyed Patients.*
Characteristic






Patients with Health 
Care–Associated 
Infections 6(N = 
452) P Value†
Sex — no. (%) 0.13
 Male 5,034 (44.6) 4,813 (44.4) 221 (48.9)
 Female 6,236 (55.3) 6,006 (55.5) 230 (50.9)
 Missing data 12 (0.1) 11 (0.1) 1 (0.2)
Age — no. (%) 0.09
 <1 yr 1,151 (10.2) 1,115 (10.3) 36 (8.0)
 1–17 yr 479 (4.2) 460 (4.2) 19 (4.2)
 18–24 yr 462 (4.1) 448 (4.1) 14 (3.1)
 25–44 yr 1,686 (14.9) 1,634 (15.1) 52 (11.5)
 45–64 yr 3,060 (27.1) 2,927 (27.0) 133 (29.4)
 65–84 yr 3,429 (30.4) 3,269 (30.2) 160 (35.4)
 ≥85 yr 1,014 (9.0) 976 (9.0) 38 (8.4)
 Missing data 1 (<0.1) 1 (<0.1) 0
Race or ethnic group — no. (%)‡ 0.09
 American Indian or Alaska Native 119 (1.1) 117 (1.1) 2 (0.4)
 Asian 254 (2.3) 244 (2.3) 10 (2.2)
 Black 1,905 (16.9) 1,809 (16.7) 96 (21.2)
 Multiple races or other unspecified race 254 (2.3) 244 (2.3) 10 (2.2)
 Native Hawaiian or other Pacific Islander 20 (0.2) 18 (0.2) 2 (0.4)
 White 7,537 (66.8) 7,244 (66.9) 293 (64.8)
 Missing data 1,193 (10.6) 1,154 (10.7) 39 (8.6)
Hispanic or Latino ethnic group — no. (%)‡ 0.04
 Hispanic or Latino 846 (7.5) 826 (7.6) 20 (4.4)
 Not Hispanic or Latino 3,715 (32.9) 3,564 (32.9) 151 (33.4)
 Missing data 6,721 (59.6) 6,440 (59.5) 281 (62.2)
Hospital size — no. (%)§ <0.001
 Small 4,073 (36.1) 3,964 (36.6) 109 (24.1)
 Medium 4,995 (44.3) 4,794 (44.3) 201 (44.5)
 Large 2,214 (19.6) 2,072 (19.1) 142 (31.4)
Location of patient in hospital on survey date — 
no. (%)¶
<0.001
 Critical care unit 1,707 (15.1) 1,551 (14.3) 156 (34.5)
 Mixed acuity unit 119 (1.1) 114 (1.1) 5 (1.1)
 Newborn or special care nursery 485 (4.3) 482 (4.5) 3 (0.7)
 Specialty care area 469 (4.2) 439 (4.1) 30 (6.6)
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Characteristic






Patients with Health 
Care–Associated 
Infections 6(N = 
452) P Value†
 Step-down unit 466 (4.1) 443 (4.1) 23 (5.1)
 Ward, not nursery 8,036 (71.2) 7,801 (72.0) 235 (52.0)
Central catheter in place on survey date — no. (%)||
 Any 2,121 (18.8) 1,862 (17.2) 259 (57.3) <0.001
  Femoral 54 (0.5) 44 (0.4) 10 (2.2)
  Peripherally inserted 1,037 (9.2) 878 (8.1) 159 (35.2)
  Other known type 1,057 (9.4) 958 (8.8) 99 (21.9)
  Unknown type 32 (0.3) 29 (0.3) 3 (0.7)
 None 9,140 (81.0) 8,948 (82.6) 192 (42.5)
 Missing data 21 (0.2) 20 (0.2) 1 (0.2)
Urinary catheter in place on survey date — no. (%) <0.001
 Yes 2,659 (23.6) 2,482 (22.9) 177 (39.2)
 No 8,594 (76.2) 8,321 (76.8) 273 (60.4)
 Missing data 29 (0.3) 27 (0.2) 2 (0.4)
Patient receiving mechanical ventilatory support on 
survey date — no. (%)
<0.001
 Yes 527 (4.7) 432 (4.0) 95 (21.0)
 No 10,748 (95.3) 10,391 (95.9) 357 (79.0)
 Missing data 7 (0.1) 7 (0.1) 0
Patient receiving or scheduled to receive 
antimicrobial therapy at time of survey — no. 
(%)**
5,860 (51.9) 5,408 (49.9) 452 (100) —
Patient receiving dialysis at time of survey — no. 
(%)
446 (4.0) 410 (3.8) 36 (8.0) <0.001
Interval from admission to survey — days
 Median 3 2 12 <0.001††
 Interquartile range 1–6 1–5 7–23
*
Percentages may not add up to 100 because of rounding.
†
P values were calculated with the use of the chi-square test, except where indicated.
‡
Race and ethnic group were determined on the basis of medical-record documentation.
§
Small hospitals had fewer than 150 beds, medium-sized hospitals had 150 to 399 beds, and large hospitals had 400 or more beds.
¶
Hospital units were defined according to the National Healthcare Safety Network classification. Critical care units included level II–III and level 
III neonatal intensive care units.
||
Patients could have more than one type of central catheter.
**
For four patients without health care–associated infections, information on antimicrobial therapy was not available on the survey date; medical 
records of these patients were reviewed retrospectively to collect data on antimicrobial therapy and health care–associated infections. By definition, 
all patients with health care–associated infections were receiving antimicrobial agents at the time of the survey.
††
The P value was calculated with the use of the Wilcoxon rank-sum test.
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Table 2
Distribution of 504 Health Care–Associated Infections.*
Type of Infection Rank No. of Infections Percentage of All Health Care–Associated Infections (95% CI)
Pneumonia† 1 (tie) 110 21.8 (18.4–25.6)
Surgical-site infection 1 (tie) 110 21.8 (18.4–25.6)
Gastrointestinal infection 3 86 17.1 (14.0–20.5)
Urinary tract infection‡ 4 65 12.9 (10.2–16.0)
Primary bloodstream infection§ 5 50 9.9 (7.5–12.8)
Eye, ear, nose, throat, or mouth infection 6 28 5.6 (3.8–7.8)
Lower respiratory tract infection 7 20 4.0 (2.5–6.0)
Skin and soft-tissue infection 8 16 3.2 (1.9–5.0)
Cardiovascular system infection 9 6 1.2 (0.5–2.5)
Bone and joint infection 10 5 1.0 (0.4–2.2)
Central nervous system infection 11 4 0.8 (0.3–1.9)
Reproductive tract infection 12 3 0.6 (0.2–1.6)
Systemic infection 13 1 0.2 (0.01–1.0)
*
Infections were defined with the use of National Healthcare Safety Network criteria. CI denotes confidence interval.
†
A total of 43 pneumonia events (39.1%) were associated with a mechanical ventilator.
‡
A total of 44 urinary tract infections (67.7%) were associated with a catheter.
§
A total of 42 primary bloodstream infections (84.0%) were associated with a central catheter.
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Table 4





Surveyed Patients with 
Type of Infection
Estimated Infections in the United 
States*
no. % (95% CI) no. (95% CI)
All health care–associated infections
 Pneumonia 110 24.3 (20.6–28.5) 157,500 (50,800–281,400)
 Surgical-site infection 110† 24.3 (20.6–28.5) 157,500 (50,800–281,400)
 Gastrointestinal infection 86 19.0 (15.6–22.8) 123,100 (38,400–225,100)
 Urinary tract infection 65 14.4 (11.4–17.9) 93,300 (28,100–176,700)
 Primary bloodstream infection 50 11.1 (8.4–14.2) 71,900 (20,700–140,200)
 Eye, ear, nose, throat, or mouth infection 28‡ 6.2 (4.2–8.7) 40,200 (10,400–85,900)
 Lower respiratory tract infection 20 4.4 (2.8–6.6) 28,500 (6900–65,200)
 Skin and soft-tissue infection 16 3.5 (2.1–5.6) 22,700 (5200–55,300)
 Cardiovascular system infection 6 1.3 (0.5–2.7) 8,400 (1200–26,700)
 Bone and joint infection 5 1.1 (0.4–2.4) 7,100 (1000–23,700)
 Central nervous system infection 4 0.9 (0.3–2.1) 5,800 (700–20,700)
 Reproductive tract infection 3 0.7 (0.2–1.8) 4,500 (500–17,800)
 Systemic infection 1 0.2 (0.01–1.1) 1,300 (0–10,900)
Total 721,800 (214,700–1,411,000)
Infections in non-neonatal intensive care units
 Catheter-associated urinary tract infection 25 5.5 (3.7–7.9) 35,600 (9100–78,000)
 Central-catheter–associated primary 
bloodstream infection
11 2.4 (1.3–4.2) 15,600 (3200–41,500)
 Ventilator-associated pneumonia 35 7.7 (5.5–10.5) 49,900 (13,600–103,700)
Surgical-site infections attributed to Surgical Care 
Improvement Project procedures§
46 10.2 (7.6–13.2) 66,100 (18,700–130,300)
Hospital-onset infections caused by specific pathogens
 Clostridium difficile infection¶ 56 12.4 (9.6–15.7) 80,400 (23,700–155,000)
 MRSA bacteremia|| 7 1.5 (0.7–3.0) 9,700 (1700–29,600)
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*
Estimates are based on an overall estimate of 648,000 patients (95% CI, 246,400 to 987,300) with at least one health care–associated infection in 
2011. To calculate the numbers of estimated infections, the point estimate of the percentage of patients with a particular type of infection (e.g., 
24.3% for pneumonia) was multiplied by the point estimate of the overall number of patients with health care–associated infections. To calculate 
the 95% CIs, the lower bound of the 95% CI for the percentage of patients with a particular type of infection (e.g., 20.6% for pneumonia) was 
multiplied by the lower bound of the 95% CI for the overall number of patients with health care–associated infections, and the upper bound of the 
95% CI for the percentage of patients with a particular type of infection (e.g., 28.5% for pneumonia) was multiplied by the upper bound of the 95% 
CI for the overall number of patients with health care–associated infections.
†
There were 110 surgical-site infections in 109 patients. For the purposes of estimating the total number of such infections in the United States in 
2011, we assumed that each of the 110 infections occurred in a unique patient.
‡
There were 28 eye, ear, nose, throat, or mouth infections in 27 patients. For the purposes of estimating the total number of such infections in the 
United States in 2011, we assumed that each of the 28 infections occurred in a unique patient.
§
Surgical Care Improvement Project procedures included those with the following National Healthcare Safety Network procedure codes: CARD, 
CBGB, CBGC, AAA, CEA, PVBY, COLO, REC, HYST, VHYS, HPRO, and KPRO.35
¶
C. difficile infection was defined by an onset of symptoms on or after the third day of hospitalization (with the day of admission counted as the 
first day).
||
Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia was defined as primary or secondary MRSA bloodstream infection with an onset 
of symptoms on or after the third day of hospitalization (with the first day of admission counted as the first day).
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